DMD Manuscript # 42721

Use of Baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells

Suneet Shukla, Candice Schwartz, Khyati Kapoor, Abdul Kouanda, Suresh V Ambudkar

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH,
Bethesda, MD 20892
DMD Manuscript # 42721

Running title page

a) Running title: BacMam vectors for transient expression of transport proteins

b) Corresponding author: Dr. Suresh V. Ambudkar. Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, MD 20892-4256, USA. (Tel: 301-402-4178, Fax: 301-435-8188; E-mail: ambudkar@helix.nih.gov)

c) Numbers of text pages: 36
   Number of Tables: 1
   Number of Figures: 5
   Number of references: 30
   Number of words in abstract: 250
   Number of words in introduction: 714
   Number of words in discussion: 1325

d) Nonstandard abbreviations: ABC, ATP-binding cassette; FTC, Fumitremorgin C; IAAP, iodoarylazidoprazosin; MDR, multidrug resistance; Pgp, P-glycoprotein
Abstract

ABC drug transporters ABCB1 (P-glycoprotein, Pgp) and ABCG2 are expressed in many tissues including those of the intestines, the liver, the kidney and the brain and are known to influence the pharmacokinetics and toxicity of therapeutic drugs. In vitro studies involving their functional characteristics provide important information which allows improvements in drug delivery or drug design. In this study, we report use of the BacMam (Baculovirus-based expression in mammalian cells) expression system to express and characterize the function of Pgp and ABCG2 in mammalian cell lines. BacMam-Pgp and BacMam-ABCG2 baculovirus-transduced cell lines showed similar cell surface expression (as detected by monoclonal antibodies with an external epitope) and transport function of these transporters when compared to drug-resistant cell lines that over-express the two transporters. Transient expression of Pgp was maintained in HeLa cells for up to 72 h after transduction (48 h after removal of the BacMam virus). These BacMam-baculovirus-transduced mammalian cells expressing Pgp or ABCG2 were used for assessing the functional activity of these transporters. Crude membranes isolated from these cells were further used to study the activity of these transporters by biochemical techniques such as photo-cross-linking with transport substrate and ATPase assays. In addition, we show that the BacMam expression system can be exploited to co-express both Pgp and ABCG2 in mammalian cells to determine their contribution to the transport of a common anti-cancer drug substrate. Collectively, these data demonstrate that BacMam-baculovirus-based expression system can be used to simultaneously study the transport function and biochemical properties of ABC transporters.
Introduction

During the preclinical stages of drug development, a new drug under investigation is tested extensively in the laboratory to ensure its safety in further clinical trials. The failure rate of drugs tested in clinical studies still remains high, due to unexpected toxicity or poor pharmacokinetic properties which prevent them from reaching the intended target in therapeutic doses (Arrowsmith, 2011). This can be credited to the way these tested drugs penetrate biological barriers such as the intestinal wall, blood-brain barrier or cell membrane (Tsaioun et al., 2009).

The ATP-binding cassette (ABC) drug transporters, P-glycoprotein (Pgp, ABCB1) and ABCG2, are expressed in many such biological barriers including those of the intestine, liver, kidney, brain, placenta, adrenal glands and testes. These transporters play key roles in determining the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of the drugs (Borst and Elferink, 2002; Glavinas et al., 2004; Szakács et al., 2008). Developing robust in vitro assays in preclinical studies to characterize ADMET properties of candidate drugs specifically related to their interactions with ABC drug transporters can help to improve the pharmacokinetic and pharmacodynamic properties of lead drug molecules. These assays not only help to improve productivity in the field of new drug development but also increase the chances of successful clinical trials with new molecules.

Several established methods are used in preclinical drug development to identify the interactions of a drug with transporters (Lai et al., 2010). These assays can be broadly classified into two categories: cell-based and membrane-based assays (Calcagno et al., 2007; Glavinas et al., 2008). In cell-based assays, transport of the candidate drug across the cell membrane is measured in a polarized monolayer using in vitro cultured cells. This approach closely mimics the small intestine and blood-brain barrier and can potentially identify drug efflux or drug-drug
interactions if influenced by ABC transporters. In membrane-based assays, inside-out plasma membrane vesicles are isolated from the cell lines over-expressing ABC transporters and transport of the drug into the lumen of these vesicles is measured in the presence or absence of ATP, the energy source. This method enables determination of the kinetic parameters of drug interactions with ABC transporters. These two approaches to determining the interactions of candidate drugs with ABC drug transporters rely on two separate in vitro cell-based culture systems that are very different in nature. Caco cells are the most popular for cell-based assays, as these cells can be grown in a monolayer that can be polarized for transport assays. Insect cells (Hi-five, SF9), which can be grown in monolayers or in suspension cultures, are capable of over-expressing high levels of transporters for vesicular transport assays (Calcagno et al., 2007).

Quite obviously, the over-expression of transporters in two different expression systems can result in inconsistencies when seeking to develop robust assays during preclinical drug development in the context of ABC drug transporters. The aim of this study was to develop an expression system for both cell-based and membrane-based assays in which ABC transporters can be transiently over-expressed in mammalian cells. We used the BacMam (Baculovirus-based expression in mammalian cells) expression system to study the function of two major ABC drug transporters, Pgp and ABCG2 in in vitro cultured mammalian cell lines. The BacMam system uses modified insect cell baculovirus vectors with a cytomegalovirus promoter instead of a polyhedron promoter to efficiently express genes in mammalian cells with minimal effort and without pleiotropic effects due to exposure to drugs used for selection (Condreay et al., 1999). Several commonly used mammalian cell lines were transduced with BacMam baculovirus-expressing ABCB1 (BacMam-Pgp) or ABCG2 (BacMam-ABCG2) for 24 h. The BacMam baculovirus-transduced cells expressed high levels of functional Pgp and ABCG2 on the cell...
surface. The expression levels of these transporters were similar to those observed in drug-resistant cell lines that over-express them. Thus, the baculovirus system can be used for expression of ABC drug transporters either in insect cells to obtain large quantities of purified protein for structural studies or in mammalian cells for mutational analysis and functional characterization in a homologous system. In aggregate, the results demonstrate the efficacy of the BacMam baculovirus system for the transduction of commonly used mammalian cell lines to over-express the ABC drug transporters Pgp and ABCG2 either individually or simultaneously, which could be used to study drug transporter interactions in preclinical studies.
Methods

Chemicals

Rhodamine 123, mitoxantrone and doxorubicin were obtained from Sigma Chemical (St. Louis, MO). Pheophorbide A was from Frontier Scientific (Logan, UT). Calcein-AM was purchased from Invitrogen Corporation (Carlsbad, CA). Fumitremorgin C (FTC) was synthesized by Thomas McCloud, Developmental Therapeutics Program, Natural Products Extraction Laboratory, NCI, NIH (Bethesda, MD). Tariquidar (XR 9576) was kindly provided by Dr. Susan Bates, National Cancer Institute, NIH. [125I]-Iodoarylazidoprazosin (IAAP) (2200 Ci/mmol) was purchased from Perkin Elmer Life Sciences (Wellesley, MA).

Cell lines

HeLa, MCF7, HEK293, KB 3-1, KB-V1 and MCF7-FLV 1000 cell lines were cultured in DMEM media supplemented with 10% FBS, 1% glutamine, and 1% penicillin. KB-V1 and MCF7-FLV 1000 cells were selected in 1 µg/ml vinblastine and 1 µM flavopiridol, respectively. S1, UACC257, HEMn, Cos-7, LLCPK1 and SKMEL28 were cultured in the media specified by ATCC.

Cloning and amplification of BacMam-Pgp and BacMam-ABCG2 viruses

The expression clones for Pgp and ABCG2 were generated in pDest-625, as previously described (Barsoum et al., 1997). The expression clones were then transformed into E. coli DH10Bac cells from Invitrogen (Carlsbad, CA), and plated on selective media containing gentamycin, kanamycin, tetracycline, IPTG, and X-gal as per the manufacturer’s protocols. White colonies were selected from these plates and bacmid DNA was generated by alkaline lysis plasmid preparation, which was further verified by PCR amplification across the bacmid junctions.
**BacMam transduction**

The BacMam-Pgp or BacMam-ABCG2 virus was added to HeLa cells (2.5 million) at a titer of 50-60 viral particles per cell (other virus particles: cell ratios are given in the figure legends) in 3 ml of DMEM and incubated for 1 hour at 37°C. DMEM medium up to 20 ml was then added to these infected cells and the cells were further incubated for 3-4 hrs. 10 mM butyric acid was then added and the cells were incubated for another 20 hours at 37°C. Similar conditions were also used for the transduction of the other cell lines listed in Table 1. After 24 hrs, the cells were trypsinized, washed, counted and analyzed by flow cytometry for cell surface expression and the function of these transporters.

**Flow cytometry**

Pgp- or ABCG2-mediated transport was determined by flow cytometry using the fluorescent compounds calcein-AM and either pheophorbide A or mitoxantrone, respectively, as previously described (Tiberghien and Loor, 1996; Robey et al., 2004). Briefly, cells were trypsinized and incubated with 0.5 µM calcein-AM (for Pgp-mediated transport) for 10 min or 5 µM pheophorbide A or mitoxantrone (for ABCG2-mediated transport) for 45 min in the presence or absence of 2 µM XR9576 (tariquidar, a Pgp inhibitor) or Fumitremorgin C (FTC, an ABCG2 inhibitor). Cells were washed with cold PBS before analysis.

Cell surface expression of Pgp and ABCG2 was examined with MRK16 antibody (from Kyowa Medex Company, Japan for Pgp-expressing cells) or 5D3 antibody, respectively, (from eBioscience, San Diego, CA for ABCG2-expressing cells), as described earlier with minor modifications (Hamada and Tsuruo, 1986; Ozvegy-Laczka et al., 2005). Pgp-expressing cells (200,000 cells) were incubated with MRK16 antibody (1 µg per 100,000 cells for Pgp) for 60 min (for Pgp-expressing cells). Cells were subsequently washed and incubated with FITC-
labeled anti-mouse secondary antibody (1 µg per 100,000 cells for Pgp; BD Biosciences, San Jose, CA) for 30 min at 37°C. The ABCG2-expressing cells were incubated with 5D3 antibody conjugated with PE (1 µg per 100,000 cells) for 45 min at 37°C. The cells were washed with cold PBS and analyzed.

Calcein, FITC and PE fluorescence was measured on a FACSort flow cytometer equipped with a 488 nm argon laser and 530 nm bandpass filter or confocal microscope; mitoxantrone and APC fluorescence was measured by a FACSort flow cytometer with a 635 nm red diode laser and a 561 nm long pass filter or confocal microscope.

[^125I]-IAAP transport assay

The[^125I]-IAAP transport assay was performed as described earlier (Shukla et al., 2006). Briefly, BacMam-Pgp (wild-type) or BacMam-Pgp-EQ-transduced cells (2.5 × 10^5 cells/well) were grown in a monolayer in a 24-well tissue culture plate at 37°C. The assay was initiated by incubating cells with 1.5 nM[^125I]-IAAP in the absence or presence of 5 µM XR 9576 at room temperature for 60 min in 0.3 ml of complete DMEM media. The cells were washed with ice-cold PBS and lysed by incubation with 0.3 ml of trypsin-EDTA/well at 37°C for 30 min. The cell lysates were transferred to scintillation vials containing 5 ml of Bio-Safe II scintillation fluid, and the radioactivity was measured in a scintillation counter. The accumulation of[^125I]-IAAP was expressed as picomoles per 1 million cells.

Cytotoxicity assays

The BacMam-Pgp-transduced cells were plated at a density of 200,000 cells/well in a 24 well plate and incubated for 24 h at 37°C in 5% CO2. Various concentrations of doxorubicin were subsequently added and plates were allowed to incubate for 24 h at 37°C in 5% CO2. 0.2% trypan blue dye was then added to cells and the viable cells were counted as the % of cells that
excluded trypan blue dye compared to total cells as described (Strober, 2001). The cell viability was then determined by calculating the number of cells that did not take up trypan blue dye. Each concentration was tested in quadruplicate.

**Preparation of crude membranes from BacMam baculovirus-transduced HeLa and baculovirus-infected High-five insect cells**

Crude membranes from BacMam-transduced cells were isolated as described earlier (Gribar et al., 2000). Crude membranes of Pgp or ABCG2 expressing High-five cells were prepared essentially as described previously (Kerr et al., 2001). Crude membranes of HeLa or High-five cells were stored in aliquots at -70°C.

**Photoaffinity labeling of Pgp with [125I]-IAAP**

Crude membranes (1 mg protein/ml) from BacMam-Pgp-transduced HeLa cells and Pgp-expressing High-five insect cells were photo-labeled with [125I]-IAAP (2200 Ci/mmole) (Perkin Elmer Life Sciences, Wellesley, MA) in the absence or presence of 10 µM cyclosporine A and 10 µM XR 9576, as described previously (Shukla et al., 2006).

**ATPase assay**

Crude membrane protein (100 µg protein/ml) from BacMam-Pgp-transduced HeLa cells and High-five insect cells expressing Pgp was incubated at 37°C with 30 µM verapamil in the presence and absence of 0.3 mM sodium orthovanadate and the ATP hydrolysis was measured as described previously (Ambudkar, 1998). The vanadate-sensitive Pgp-ATPase activity is expressed as nmolesP/min/mg protein.

**SDS-PAGE and Western blot analysis**
Cell lysates or crude membrane proteins were resolved on 7% Tris-acetate gels. Pgp and ABCG2 in immunoblots were detected with monoclonal antibodies C219 (Kartner et al., 1985) and BXP-21 (Maliepaard et al., 2001), respectively at 1:2000 dilution.
Results

**HeLa cells transduced by BacMam-Pgp virus over-express functional Pgp**

HeLa cells were transduced with BacMam-Pgp virus at a titer of 1:50-60 (50-60 viruses/cell) for 24 hrs as described in the methods section. The cell surface expression of Pgp was monitored by confocal microscopy and flow cytometry using the Pgp-specific MRK16 antibody and as shown in Figure 1a and 1b (left panel). These transduced cells expressed levels of Pgp comparable to those of KB-V1 (drug selected HeLa) cells, which are known to over-express high levels of Pgp (Shen et al., 1986). These Pgp-expressing transduced cells were able to efflux calcein-AM, a known substrate of Pgp, with efficiency similar to that observed in the KB-V1 cells (Figure 1b, right panel). The multiplicity of infection (MOI) for viral infection was titrated to yield maximum Pgp expression with minimal perturbation to cell integrity because of the viral infection. The expression and function of Pgp was optimal and saturated at an infection titer of 50-60 viral particles/cells (data not shown). Butyric acid, a histone deacetylase inhibitor, was added, as earlier reports showed that it was able to increase the protein expression in transduced cells (Condrey et al., 1999). Maximal expression and function of Pgp was observed in the presence of 10 mM Butyric acid based on a butyric acid titration curve (1 to 10 mM; data not shown). Thus, this concentration of butyric acid was used in all further experiments.

Viral-based induced expression of protein in mammalian cells generally has a cytostatic or cytotoxic effect on the cells that is caused by the viral infection. In order to ensure that BacMam-Pgp-transduced cells could further be used for functional transport assays using intact cells, the activity of Pgp was monitored in both short and long-term assays such as transport and cytotoxicity assays, respectively. The data presented in Figure 1c shows that these cells were able to efflux [125I]-IAAP, resulting in decreased intracellular accumulation in a 60-min assay.
The total accumulation of $[^{125}\text{I}]-\text{IAAP}$ in Pgp-expressing HeLa cells was 0.088 pmoles/million cells, which was almost two-fold lower than the accumulation in control HeLa cells, measured to be 0.157 pmoles/million cells. This Pgp-mediated efflux of $[^{125}\text{I}]-\text{IAAP}$ was completely inhibited by 2 μM XR9576, an inhibitor of Pgp function. In addition, we also transduced HeLa cells with BacMam-Pgp-EQ virus, which expresses a non-functional mutant Pgp (E556Q/E1201Q) with the glutamate residue in the Walker B motif of each nucleotide-binding domain that is changed to glutamine (Sauna et al., 2002). The accumulation of $[^{125}\text{I}]-\text{IAAP}$ in these cells was comparable to that seen in control HeLa cells, suggesting that the viral infection of the cells per se does not have any effect on the permeability properties of the plasma membranes of these cells.

The ability of the intact cells to confer drug resistance in long-term assays such as cytotoxicity assays was also evaluated by trypan blue viability assays. This was assessed at 48 hrs after viral transduction (24 h after addition of doxorubicin as described in the methods section). As shown in Figure 1d, the cells expressing Pgp were resistant to doxorubicin-induced cell death compared to the control, untransfected HeLa cells. These results suggested that the virally-transduced Pgp over-expressing cells were capable of expressing very high levels of functional Pgp up to 48 hrs after transfection and are suitable for functional assays of Pgp activity. In addition, it was observed that the cells were in fact able to express fairly good amounts of functional Pgp up to 72 hrs after transfection (Figure S1 a and b) with the half-life of the cell surface Pgp about 55-60 hrs in this system.

We also evaluated the use of BacMam-Pgp virus for transducing multiple cell lines that are routinely used in laboratory studies. It was observed that most mammalian cell lines can be transduced to express Pgp, though the expression level of Pgp varies, as shown in Table 1. It
should be noted that HeLa and MCF7 cells were able to express the highest level of Pgp, while KB 3-1 or NIH3T3 cells could not be transduced effectively with the BacMam-Pgp virus.

**BacMam-Pgp-transduced cells for biochemical studies**

The data above suggested that BacMam-mediated over-expression of functional Pgp can be achieved in HeLa cells. These cells can be used for functional assays whenever intact cells are required for measuring the activity of the transporters. Other viral-based systems can also be used for such functional studies, but the BacMam-based expression system is advantageous, especially in the case of ABC drug transporters, as this system can also be used for biochemical studies that require high levels of functional protein to be expressed in the membranes of transduced cells.

Crude membranes from Pgp-expressing BacMam-Pgp-transduced HeLa cells were isolated by hypotonic lysis and homogenization as described in the methods section. The crude membrane protein, after being resolved in 7% Tris-acetate gel was stained with colloidal blue and probed with C219 (a Pgp-specific monoclonal antibody) for detection of Pgp expression. A high level of Pgp was observed in crude membranes, comparable to the levels observed in Pgp expressing High-five insect cell membranes (Figure 2a), which are routinely used as a system to study the biochemical properties of functional Pgp. The Pgp expressed in HeLa cells is fully glycosylated but not in insect cells (Figure 2a). The crude membranes were further evaluated for functional Pgp activity by photolabeling and ATP hydrolysis studies. As shown in Figure 2b, Pgp could be photo-cross-linked with [\(^{125}\)I]-IAAP, which is a transport substrate and this labeling was inhibited in the presence of the competing substrates 20 \(\mu\)M cyclosporine A and 10 \(\mu\)M XR9576. It should again be noted that the levels of photo-cross-linked Pgp were similar to those observed in crude membranes from insect cells. In addition, BacMam-Pgp-expressing crude
membranes also showed basal ATPase activity (18.9 nmoles P i mg/min), which was stimulated
by approximately 2.5-fold in the presence of 30 μM verapamil.

Expression of ABCG2 in HeLa cells using BacMam baculovirus

To demonstrate the general applicability of this system, the expression and function of
another major ABC drug transporter, ABCG2, was also evaluated by transduction of HeLa cells
with BacMam-ABCG2 for 24 hr at a titer of 1:50-60. Figure 3a and b shows that ABCG2 was
over-expressed at the cell surface, as detected by the ABCG2-specific 5D3 antibody. The cell
surface expression level and function of ABCG2 was similar to MCF7-FLV1000 cells, a drug-
selected cell line that expresses very high levels of ABCG2 (Robey et al., 2001). As with Pgp,
BacMam-ABCG2-transduced cells were able to efflux mitoxantrone, a known substrate of
ABCG2, to levels comparable to those of MCF7-FLV1000 cells (Figure 3c). Total cell
expression of ABCG2 was evaluated in cell lysates prepared from BacMam-ABCG2-transduced
cells using BXP-21 antibody and ABCG2 expression was similar or higher than in MCF7-
FLV1000 cells (Figure 3d). Similar to Pgp as shown in Figure S1, the half-life of ABCG2
transporter was also in the range of 50-55 hrs (data not shown).

Co-expression of Pgp and ABCG2 in HeLa cells

The expression of transporters such as Pgp and ABCG2 can affect drug absorption,
distribution and excretion, and explain mechanisms underlying drug-drug interactions. The
regional distribution of Pgp, ABCG2 and SLC transporters along the intestine was reported
earlier but their individual contributions to the transport of specific substrates have not been
addressed (Thiebaut et al., 1987; Englund et al., 2006). Therefore, understanding the individual
contributions of two or more transporters in one system using in vitro cultured cells or an in vivo
system for an experimental drug would help to evaluate clinical drug-drug interactions.
In order to investigate further, HeLa cells were transduced with either BacMam-Pgp and BacMam-ABCG2 virus individually or co-transduced with BacMam-Pgp and BacMam-ABCG2 virus, as described in the methods section. Cell surface co-expression of Pgp and ABCG2 was monitored by confocal microscopy (Figure 4a) using MRK16 (green) and 5D3 (red) antibodies, respectively and by flow cytometry (Figure 4b), as described in the methods section. The double-transduced cells simultaneously expressed both Pgp and ABCG2 on the cell surface using different titers of the two viruses (1:40 for Pgp and 1:60 for ABCG2) (Figure 4a and b). The co-expression of Pgp and ABCG2 was also confirmed by Western blot analysis from the total cell lysates of these co-transfected cells using C219 (Figure 4c) for Pgp and BXP21 (Figure 4d) for ABCG2 detection. Both transporters were functional when co expressed, as determined by their ability to efflux calcein-AM (for Pgp, Figure 5a) and pheophorbide A (for ABCG2, Figure 5b) at the same time. It should be noted that the expression of ABCG2 in double-transduced cells (HeLa-Pgp-ABCG2) was lower than single transduced (HeLa-ABCG2) cells (Figure 4b and d). However, the efflux of pheophorbide A from both ABCG2 and Pgp transduced cells was comparable to the efflux observed in the single gene transduced cells (Figure 5b).

The two transporters co-localized on the cell surface (as seen by yellow fluorescence in the lower right panel of Figure 4a), suggesting that these two transporters can simultaneously contribute to the efflux of drugs that are non-overlapping substrates of each of these transporters. Therefore, this system can further be used to study the contribution of an individual transporter for its ability to efflux a specific substrate and/or overlapping substrates. Along these lines, transport of mitoxantrone (an anticancer agent that is transported by Pgp and ABCG2) was studied in transduced HeLa cells expressing both Pgp and ABCG2 using FACS assays (Figure
5c). The percent contribution of each transporter for effluxing mitoxantrone was calculated by subtracting the transport activity observed in double transfectants in the absence of any inhibitor from the activity observed in the presence of 5 µM FTC (a specific ABCG2 inhibitor) or 10 µM vinblastine (VBL, although a substrate, used here as a competitive inhibitor of Pgp) alone. The inhibition of efflux activity in the presence of both FTC and vinblastine was considered as 100%. It was observed that while the presence of FTC alone inhibited 27% of efflux, the presence of VBL alone resulted in 20% inhibition of mitoxantrone efflux from these cells. These data suggest that the individual activities of two transporters can be measured by using a common substrate and specific inhibitors by co-expressing these transporters using the BacMam expression system. It should be mentioned that we have not taken into consideration the affinity differences of mitoxantrone for Pgp and ABCG2 in the above experiment.
Discussion

Pgp and ABCG2 are two major ABC drug transporters that have not only been implicated in clinical drug resistance, but are also now known to have important roles in drug-drug interactions and in the pharmacokinetics of several structurally and pharmacologically diverse substrate drugs. In addition, in a draft guidance issued by the U.S. Food and Drug Administration and the European Medicines Agency, study of the transport function of Pgp and ABCG2 is recommended for in vitro and in vivo drug interaction studies to be conducted during new drug development (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072101.pdf and http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf). Therefore, development of robust cellular and biochemical tools that can aid in identifying drug-drug interactions or characterizing the transport properties of these transporters is required in the field of preclinical drug development.

In an effort to develop a transient expression system that can be used to over-express ABC drug transporters and is suitable for both cellular and biochemical assays, we report here the use of a modified baculovirus to express Pgp and ABCG2 in mammalian cells. One major advantage of the BacMam expression system is that gene delivery can be accomplished in many different cell types by simply adding viral inoculums (reviewed in (Kost et al., 2005)). Using this system, we showed that both Pgp and ABCG2 can be expressed in several routinely used in vitro cultured mammalian cell lines at levels equal to those seen in drug-selected cell lines (Figures 1 and 3). These transiently transduced cells can also be used to study the function of the transporters in intact cell-based assays such as accumulation assays using fluorescent or
radiolabeled substrates or cytotoxicity assays. The virally-transduced cells were able to express protein at considerably high levels for up to 72 hrs after transduction and can therefore be used to study the function and biochemical properties of the transporters in long-term assays.

There are basically two different cell-based assays that are frequently used to determine interactions with transporters. The first is the cellular uptake assay and the second is an assay that measures bidirectional transport across polarized cell monolayers. We show that the Pgp-expressing transduced cells can be used to measure $[^{125}\text{I}]-\text{IAAP}$ transport (a known substrate) mediated by this transporter. These cells can further be used to measure the uptake of a probe substrate, whether radiolabeled, fluorescent, or one for which the LC-MS/MS analytical method has been validated. In addition, the uptake of these probes can be monitored in the presence and absence of test compounds to identify potential modulators or drugs that can cause potent drug-drug interactions.

We were also able to co-express both Pgp and ABCG2 by transducing the cells with BacMam-Pgp and BacMam-ABCG2 virus. The relative contributions of each transporter to the efflux of a common substrate, mitoxantrone, was evaluated in these cells by using specific inhibitors of Pgp and ABCG2 (vinblastine for Pgp and FTC for ABCG2) function (Figure 5c). This co-expression system therefore can also be used to assess the individual contributions of two or more transporters (that have overlapping substrate specificities) in effluxing clinically important anti-cancer drugs. It should be noted that the uptake or efflux of many anti-cancer drugs is influenced by several transporters and even double-transduced cell lines may not predict the true in vivo situation. Earlier, a BacMam-based expression system was used to co-express ABCG2 and OATP1B1 in mammalian cells (Hassan et al., 2006). The report showed simultaneous expression of two transporters but did not use the expression system for further
biochemical studies of the transporters. Very recently, Poller et al reported stable co-expression of human ABCB1 and ABCG2 using a polarized MDCKII cell line and studied the interplay of both transporters by measuring transepithelial transport of clinically used drugs including topotecan, sorafenib and sunitinib, which are substrates of these transporters (Poller et al., 2011). They showed that the relative impact of these transporters can influence the availability of the above drugs at the blood-brain barrier. Although polarized cells can be used to measure direct efflux, setting up polarized cell lines for transport assays can be cumbersome, as relatively few cell lines (Caco-2, MDCK, LLC-PK1 and HT-29) form confluent, polarized monolayers. Moreover, depending on the cell line and the protocol, cells need to be cultured for one to three weeks to form confluent, polarized monolayers with tight junctions. In contrast, the BacMam-based expression system can not only be used to co-express these two transporters, but could possibly be used in a high throughput manner to study the transport properties of specific substrates.

For biochemical characterization of the substrate interactions with transporter proteins, generally crude membranes or purified plasma membranes vesicles are isolated from cells over-expressing the transporters and assays such as ATP hydrolysis, photoaffinity binding assays and vesicular transport assays are performed. The most commonly used cells for expressing transporter protein and preparing vesicles are insect Sf9 cells (Glavinas et al., 2008). However, the membrane composition of the insect Sf9 cell plasma membrane is different from that of mammalian plasma membranes and has been shown to significantly affect transporter functionality (Pál et al., 2007). Therefore expression of mammalian ABC drug transporters is most likely to approximate physiological levels when it occurs in human cells. Also, the membranes isolated from these cells expressed very high levels of transporters compared to the
levels observed in insect cells (Figure 2). An advantage of using the BacMam system is that
unlike what happens in insect cells, the over-expressed protein undergoes normal post-
translational modification such as glycosylation, as evident from the Western blot analysis in
Figure 2. Crude membranes isolated from Pgp-expressing HeLa cells were further used for both
photoaffinity binding assays using $^{[125]}$I-IAAP and ATPase assays and exhibited properties
similar to those of Pgp expressed in insect cells. The above data suggested that BacMam-based
expression of ABC transporters is not only suitable for intact cell studies, but that membranes
isolated from these cells can further be used to study the biochemical characteristics of the
expressed protein and kinetic characterization of drug interactions with these transporters. In
addition, because of such high levels of expression, this system can be used for mutational
analysis in a homologous system as well as for purification, reconstitution, and possible
structural studies of ABC transporters.

There are multiple advantages of using the BacMam-based expression system in
mammalian cells (reviewed in (Kost et al., 2007)). While the BacMam viruses can transduce
many cell types including many primary cells, the proteins can be expressed using different
stocks of virus, whereas only a single mammalian cell line has to be maintained. The BacMam-
baculovirus transduced cells show little or no microscopically observable cytotoxic effect, so this
system can be used to co-express multiple proteins. Moreover, the expression levels can be easily
controlled by titration of the virus ratio to that of the cells. Baculovirus-mediated gene
expression also has the advantage of good bio-safety, as the virus only replicates in insect cells
and is incapable of replicating in mammalian cells. Our data (supplementary Figure S2) further
suggest that BacMam-transduced cells can be stored at -80°C or in liquid nitrogen for long
periods of time and can be taken out for immediate usage in case of functional studies.
Therefore, the BacMam system can be used to produce quantities of transduced cells (or multiple cells) expressing single or multiple transporters that can be stored in freezers and used later for functional studies as and when needed; maintaining multiple cell lines in culture rooms is not necessary. This could be of particular interest in pharmaceutical industrial application as the system provides a platform for high throughput study of drug-drug interactions with the transporters.

In conclusion, the BacMam-based expression system for ABC drug transporters in human and other mammalian cells can be used for biochemical and functional studies of Pgp and ABCG2 and perhaps other ABC transporters in a single system. We suggest that this system will be very useful to determine the contributions of at least two major ABC drug transporters simultaneously to the efflux of lead drug compounds in preclinical studies.
Acknowledgements

We thank George Leiman for editorial assistance.
DMD Manuscript # 42721

Authorship Contributions

*Participated in research design*: Shukla, Ambudkar.

*Conducted experiments*: Shukla, Schwartz, Kapoor, Kouanda

*Contributed new reagents or analytic tools*: Shukla, Ambudkar

*Performed data analysis*: Shukla, Schwartz, Kapoor, and Ambudkar.

*Wrote or contributed to the writing of the manuscript*: Shukla, Schwartz, Kapoor, and Ambudkar.
DMD Manuscript # 42721

References


DMD Manuscript # 42721


discovery and development. *Comb Chem High Throughput Screen* **13**:112-134.

Maliepaard M, Scheffer GL, Faneyte IF, Van Gastelen MA, Pijnenborg ACLM, Schinkel AH,
Van de Vijver MJ, Scheper RJ, and Schellens JHM (2001) Subcellular localization and
distribution of the Breast Resistance Protein Transporter in normal human tissues. *Cancer
Res* **61**:3458-3464.

Ozvegy-Laczka C, Varady G, Koblos G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP,
conformational changes of the ABCG2 multidrug transporter modify its interaction with

Pál Á, Méhn D, Molnár É, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáky T, von Richter O,
Heterologous Expression System: Improved in Vitro Model to Study Function of Human

Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)

Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz
AM, Ross DD, and Bates SE (2001) Overexpression of the ATP-binding cassette half-
transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer
DMD Manuscript # 42721


DMD Manuscript # 42721


BMC Neurology 9:S1.
Footnotes

a) This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and the Office of Dietary Supplements, NIH.

b) Reprint requests should be sent to: Dr. Suresh V. Ambudkar. Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, MD 20892-4256, USA (Tel: 301-402-4178, Fax: 301-435-8188; E-mail: ambudkar@helix.nih.gov).
Figure legends:

**Figure 1: BacMam-Pgp-transduced HeLa cells express functional Pgp.** (a, b) BacMam-Pgp virus transduced HeLa (panel a) and KB-V1 cells were incubated with either 0.5 µM calcein-AM for 10 min in the presence and absence of 2 µM XR9576 or MRK16 antibody (1 µg/100,000 cells) for 1 hour at 37°C followed by incubation with FITC conjugated anti-mouse secondary antibody. The cells were washed and subsequently analyzed by confocal microscopy (a) or flow cytometry (b), as described in the methods section. (a) Left panel shows cell surface localization of Pgp as detected by green fluorescence detector. Middle panel shows nuclear staining of cells with DAPI, a nuclear counter stain, as detected by blue fluorescence detector. Right panel shows an overlay of green and blue fluorescence. (b) The histogram shows fluorescence (x-axis) representing surface expression as detected by MRK16 labeling in the left panel and calcein accumulation in the right panel plotted as a function of the number of cells (Y-axis). Individual histograms are labeled as shown and represent a single experiment that was done independently at least three times. Vinblastine-selected Pgp-expressing KB-V1 cells (Shen et al., 1986) were used for comparison in both panels. (c) $^{125}$I-IAAP is transported by HeLa cells transduced with BacMam-Pgp. The control HeLa, HeLa cells expressing wild-type Pgp (HeLa-Pgp) or inactive mutant Pgp (HeLa-Pgp-EQ) cells (0.25 × 10$^6$ cells/well) were incubated with 3-5 nM $^{125}$I-IAAP in the absence (dark grey) or presence (light grey) of 2 µM tariquidar (XR9576) at room temperature for 60 min in DMEM medium. The amount of radioactive drug that accumulated in the cells was measured by liquid scintillation counting, as described in the methods section. The graph shows the amount of $^{125}$I-IAAP that accumulated (picomoles per 1 million cells) in the cells. The mean values from three independent experiments that were performed in duplicate sets are shown here, and error bars indicate the standard deviation. (d)
BacMam-Pgp-transduced HeLa cells confer resistance to doxorubicin. Cytotoxicity assays for Pgp-expressing transduced HeLa cells (filled squares) and control HeLa cells (filled stars) are shown. Dose-response curves were derived from three independent experiments using the trypan blue viability assay as described in the methods section and the error bars indicate standard deviation.

**Figure 2: Crude membranes of BacMam-Pgp transduced HeLa cells over-express functional Pgp.** (a) Colloidal blue stain (left panel) and Western blot analysis (right panel) of crude membranes (10 μg protein for colloidal blue and 2 μg protein for Western blots) isolated from control HeLa cells (lane 1), HeLa cells transduced with BacMam Pgp (lane 2) and Hi-five insect cells expressing Pgp (lane 3). Immunoblotting with C219, a Pgp specific antibody was carried out as described in the methods section. The arrows represent glycosylated (upper) or non-glycosylated (lower) forms of Pgp. (b) **Pgp expressed in BacMam-Pgp-transduced HeLa cells can be photo-labeled with [125I]-IAAP.** Crude membranes (500 μg protein/ml) from control HeLa (lanes 1-3), Pgp-expressing HeLa (lanes 4-6) or Hi-five insect cells expressing Pgp (lanes 7-9) cells were incubated for 5 min at room temperature in the absence (lanes 1, 4, 7) or presence of 20 μM cyclosporin A (lanes 2, 5, 8) or 10 μM tariquidar (lanes 3, 6, 9) in 50 mM Tris-HCl (pH 7.5) and 3-6 nM [125I]-IAAP (2200 Ci/mmol) was added. The samples were then photo-cross-linked with [125I]-IAAP, as described in the methods section. The autoradiogram from a representative experiment is shown, and the arrow represents the position of glycosylated and unglycosylated forms of Pgp. A representative experiment from three independent experiments is shown here. (c) **Pgp expressed in crude membranes of BacMam transduced-HeLa cells exhibits substrate (verapamil)-stimulated ATPase activity.** Crude membranes (100 μg protein/ml) from Pgp-expressing Hi-five or HeLa cells were incubated at 37°C in the
absence (dark grey) or presence (light grey) of 30 μM verapamil in the presence and absence of 0.3 mM sodium ortho vanadate in ATPase assay buffer for 5 min and the vanadate-sensitive ATPase activity of Pgp was determined as described in the methods section. The histograms represent the ATPase activity (mean values ± the standard deviation) from three independent experiments.

**Figure 3: BacMam-ABCG2-transduced HeLa cells express functional ABCG2.** (a, b, c) BacMam-ABCG2-virus-transduced HeLa (panel a) and MCF7FLV 1000 cells were incubated with either 5D3-PE antibody (1 μg/100,000 cells) for 1 hour at 37°C or 5 μM mitoxantrone for 45 min in the presence or absence of 5 μM FTC. The cells were washed and subsequently analyzed by confocal microscopy (a) or flow cytometry (b, c) as described in the methods section. (a) Left panel shows cell surface localization of ABCG2 as detected by a red fluorescence detector. Middle panel shows nuclear staining of cells by DAPI, a nuclear counter stain as detected by a blue fluorescence detector. Right panel shows an overlay of red and blue fluorescence. (b, c) The histograms show fluorescence (x-axis) representing surface expression as detected by 5D3 labeling (panel b) and mitoxantrone accumulation (panel c) plotted as a function of number of cells (Y-axis). Individual histograms are labeled in the figure and represent a single experiment which was done independently three times. (d) Western blot analysis of total cell lysates (5 μg protein/lane) isolated from control HeLa cells (lane 1), HeLa cells transduced with BacMam-ABCG2 (lane 2) and MCF7-FLV1000 cells expressing ABCG2 (lane 3). Immunoblotting with BXP-21, an ABCG2-specific antibody, was carried out as described in the methods section. The arrows show the position of glycosylated (upper) or non-glycosylated (lower) forms of ABCG2.
Figure 4: Co-expression of both Pgp and ABCG2 in HeLa BacMam baculovirus-transduced cells: HeLa cells were transduced with both BacMam-Pgp and BacMam-ABCG2 (1:40 virus titer for Pgp and 1:60 virus titer for ABCG2), as described in the methods section, for 24 hrs. After 24 h, transduced HeLa cells were labeled by 5D3 (upper left panel) or MRK16 (upper right panel) antibodies as described in the methods section and the cells were analyzed by confocal microscopy. Lower left panel shows nuclear staining of cells by DAPI as detected by blue fluorescence detector. Lower right panel shows an overlay of red, green and blue fluorescence. (b) The cell surface expression of Pgp (left panel) and ABCG2 (right panel) in a single- or double-transduced cells (as indicated on histograms) was detected by MRK16 antibody (for Pgp) and 5D3 antibody (for ABCG2) as described in the methods section. The histograms represent fluorescence intensity (X-axis) plotted as a function of cell number (Y-axis) and are representative of three independent experiments. (c, d) Western blot analysis of total cell lysates (5 μg protein/lane) from BacMam-Pgp (lane 1), BacMam-ABCG2 (lane 2) and both BacMam-Pgp and BacMam-ABCG2 together (lane 3) transduced HeLa cells, using C219 antibody (c) and BXP-21 antibody (d) was performed as described in the methods section. The arrows represent the position of the Pgp band in panel a and the ABCG2 band in panel b.

Figure 5: Both Pgp and ABCG2 in are functionally expressed in HeLa cells co-transduced with BacMam-Pgp and BacMam-ABCG2 viruses (a, b) HeLa cells were co-transduced with BacMam-Pgp and BacMam-ABCG2 (1:40 virus titer for Pgp and 1:60 virus titer for ABCG2) alone or together, as described in the methods section. The function of Pgp (a) and ABCG2 (b) in single- or double-transduced cells (as indicated on histograms) was evaluated by calcein-AM accumulation assay in the presence or absence of 2 μM XR9576 (for Pgp) and pheophorbide A accumulation assay in the presence or absence of 5μM FTC (for ABCG2) as described in the
methods section. The histograms represent fluorescence intensity (X-axis) plotted as a function of cell number (Y-axis) and are representative of three independent experiments. (c)

**Determination of contribution of Pgp and ABCG2 in efflux of mitoxantrone from HeLa cells transduced with both Pgp and ABCG2 BacMam virus:** HeLa cells were transduced with BacMam-Pgp, BacMam-ABCG2 or both viruses to express/co express Pgp, ABCG2 or both Pgp and ABCG2 simultaneously. The Pgp and ABCG2 transport function was detected by incubating cells with 5 µM mitoxantrone for 45 min at 37°C in the dark, in the absence or presence of 20 µM vinblastine (as an inhibitor of Pgp transport) and/or 5 µM FTC (as an inhibitor of ABCG2 function). The cells were then washed and subsequently analyzed by flow cytometry as described in the methods section. The percent contribution of each transporter to the efflux of mitoxantrone was calculated by subtracting the transport activity observed in double transfectants in the absence of any inhibitor from the activity observed in the presence of 5 µM fumitremorgin C (FTC, a specific ABCG2 inhibitor) or 20 µM vinblastine (VBL, a competitive inhibitor of Pgp) alone. The inhibition of efflux activity in the presence of both FTC and VBL was taken as 100%. Double arrows represent mitoxantrone efflux activity contributed by ABCG2 (difference between mitoxantrone alone and in the presence of 5 µM FTC) or Pgp (difference between mitoxantrone alone and in the presence of 20 µM VBL). Both FTC and vinblastine were added together to obtain complete inhibition of efflux (taken as 100% accumulation). Shown here is a graph from a single experiment which was done independently at least three times. Mito: mitoxantrone; VBL, vinblasine
Table 1: Cell surface expression and function of Pgp in multiple commonly used cell lines

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Type of cells</th>
<th>Pgp cell surface expression&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Pgp transport function&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeLa</td>
<td>Cervical cancer</td>
<td>++++&lt;sup&gt;c&lt;/sup&gt;</td>
<td>++++</td>
</tr>
<tr>
<td>MCF-7</td>
<td>Breast cancer</td>
<td>++++</td>
<td>++++</td>
</tr>
<tr>
<td>S1</td>
<td>Colon cancer</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>UACC-257</td>
<td>Melanoma</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>HEMn</td>
<td>Epidermal melanocyte</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Cos-7</td>
<td>Monkey kidney fibroblast</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>LLCPK1</td>
<td>Porcine kidney</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>SK-MEL28</td>
<td>Melanoma</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>HEK293</td>
<td>Embryonic kidney</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>NIH3T3</td>
<td>Mouse embryonic fibroblast</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>KB-3-1</td>
<td>Cervical cancer</td>
<td>±</td>
<td>±</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cell line</th>
<th>ABCG2 cell surface expression&lt;sup&gt;a&lt;/sup&gt;</th>
<th>ABCG2 transport function&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeLa</td>
<td>++++</td>
<td>++++</td>
</tr>
<tr>
<td>MCF-7</td>
<td>++++</td>
<td>++++</td>
</tr>
<tr>
<td>HEK293</td>
<td>++</td>
<td>++</td>
</tr>
</tbody>
</table>

<sup>a</sup> Cell surface expression was measured with MRK16 (for Pgp) or 5D3 (for ABCG2) monoclonal antibodies.

<sup>b</sup> The transport function of Pgp and ABCG2 was determined using calcein-AM or mitoxantrone efflux assays, respectively as described in the methods section.

<sup>c</sup> ++++; highest expression and function (similar to drug selected Pgp (KB-V1) or ABCG2 (MCF7 FLV1000) cell lines.

+++ and ++; medium expression and function

±; less than 10% expression and function